Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in Imatinib-resistant or Intolerant Ph+ CML
NCT01206088Phase 4Completed
- Sponsor
- Novartis
- Start
- Feb 2009
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nilotinib in chronic myeloid leukemia (CML), sponsored by Novartis. Primary endpoint: Complete Cytogenetic Response Rate at 12 months. Started Feb 2009; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01206088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01206088.